{"name":"Bio Sidus SA","slug":"bio-sidus-sa","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Erythropoietin alfa","genericName":"Erythropoietin alfa","slug":"erythropoietin-alfa","indication":"Anemia associated with chronic kidney disease","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Teriparatide (rDNA origin)","genericName":"Teriparatide (rDNA origin)","slug":"teriparatide-rdna-origin","indication":"Osteoporosis in postmenopausal women at high risk of fracture","status":"marketed"}]}],"pipeline":[{"name":"Erythropoietin alfa","genericName":"Erythropoietin alfa","slug":"erythropoietin-alfa","phase":"phase_3","mechanism":"Erythropoietin alfa is a recombinant human erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.","indications":["Anemia associated with chronic kidney disease","Anemia in patients with cancer receiving chemotherapy","Anemia in patients with HIV infection"],"catalyst":""},{"name":"Teriparatide (rDNA origin)","genericName":"Teriparatide (rDNA origin)","slug":"teriparatide-rdna-origin","phase":"marketed","mechanism":"Teriparatide is a recombinant human parathyroid hormone (PTH 1-34) that stimulates osteoblasts to increase bone formation and remodeling.","indications":["Osteoporosis in postmenopausal women at high risk of fracture","Osteoporosis in men at high risk of fracture","Glucocorticoid-induced osteoporosis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxOUkRsY01EVUNVYzQzbGMySGVXNlZiSUFxYmZaNGI5NjFTSE51VVFWN0NVb2lBemRqdXVTdVRvOUZNZktoU21wMTExMFRRRlozSzBEZmxiazZISFVkcDVoQ2RJa2JsSnVPMjJqcldweS0zVVlSdVVyWExHb3pzSVFQa2NiUFBxcWRRcmNfdWh1NS1DUjVpYm9MY2pwQktxU283VDFuTkxmckpDYzl4d0FIV2M0djFfdWs4dldTclBGUzZYYWsxdkZjTjRhSXg?oc=5","date":"2022-06-08","type":"pipeline","source":"GlobeNewswire","summary":"Radius Health Expands Non-US Market Footprint for TYMLOS - GlobeNewswire","headline":"Radius Health Expands Non-US Market Footprint for TYMLOS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOM2UtZm5VWUVnTXpEWHo2T2k5Z19HMFVGX2dsdG13dlRCeVlHZVotZjR0YXVIUVg3bTg2UzM3dW9RSmRKWkN1T01YMW42MjNtMWlnSnRXTEVSNngta0RrUEFZNnFhbHRJZmUwYlpOY3JsTFU0eWtCN2NxUTRRWFhCU0Nn?oc=5","date":"2021-11-19","type":"regulatory","source":"Generics and Biosimilars Initiative","summary":"Biosimilars approved in Chile - Generics and Biosimilars Initiative","headline":"Biosimilars approved in Chile","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1JSVBRZ1dmMU9jQVVlbFBMUVVKSTZxcUlUXzNjM0EzakFFcVh1eFc0b0hfSFdtdk43UjZJNTNDZkhMSFpiLWFYRWhnRHZKS0FxMGd3SjJwZnhvUFIxdG80?oc=5","date":"2020-09-01","type":"pipeline","source":"nature.com","summary":"Using a fully integrated platform to advance high-quality, affordable biologics - nature.com","headline":"Using a fully integrated platform to advance high-quality, affordable biologics","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}